400
Participants
Start Date
April 28, 2015
Primary Completion Date
June 30, 2019
Study Completion Date
June 30, 2019
Oral apixaban
To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
Subcutaneous enoxaparin
To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
University of Colorado Denver, Aurora
University of Southern California Keck School of Medicine, Los Angeles
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of Colorado, Denver
OTHER